Atria Investments Inc has increased its stake in IDEXX Laboratories, with an additional 470 shares. The company's stock has shown reasonable performance, influenced by strong financials. Currently, major ownership, to the tune of 88%, is held by institutional investors.
DekaBank Deutsche Girozentrale also amplified its position in IDEXX Laboratories. The company underperformed in comparison to its competitors albeit showing daily gains. IDEXX announced a schedule change for their Q2 2024 financial results conference call. General optimism surrounds the company's share value as well as potential for Q2. IDEXX’s corporate responsibility report for 2023 highlights success against its goals. Earnings are expected to grow, and the company is set to announce earnings soon. An
Advisors Asset Management Inc. purchase of 434 IDEXX shares signals continued interest. However, bearish signals emerge with IDEXX insiders reportedly selling stock. Prospects seem strong despite noticeable share weakness and underperformance. IDEXX's Q1 2024 earnings have surpassed estimates, but the view for 2024 has been cut. Analysts give a 'Moderate Buy' recommendation reflecting the company's solid balance. Despite a surge in expenses and currency troubles, IDEXX demonstrates strong CAG sales aiding their Q2 earnings. The introduction of new test menu for the Catalyst Platform displays commitment to global veterinary support.
Idexx Laboratories IDXX News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Sun, 04 Aug 2024 17:10:46 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -3
